Drug Profile
Sirolimus-eluting implant - Vascular Therapies
Alternative Names: Coll-R; SeCI; SirogenLatest Information Update: 31 Aug 2022
Price :
$50
*
At a glance
- Originator Vascular Therapies
- Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lactones; Macrolides; Nootropics; Polyenes; Pyridines; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Arteriovenous fistula
- No development reported Peripheral arterial disorders
Most Recent Events
- 01 Aug 2022 Vascular Therapies initiates enrolment in the phase III ACCESS 2 trial for Arteriovenous fistula in USA (Implant) (NCT05425056)
- 04 Nov 2021 Vascular Therapies plans an ACCESS 2 clinical trial to validate the sub-group analysis from ACCESS 1 trial for Arteriovenous fistula in the second quarter of 2022
- 04 Nov 2021 Vascular Therapies collaborates with the FDA to design ACCESS 2 clinical trial for Arteriovenous fistula